Case report of a patient with stage IV lung adenocarcinoma and uncommon/compound EGFR mutations who responded to afatinib

Hisanori Hirokawa; Hirokuni Hirata; Hayase Azuma; Kei Sugitate; Sayo Soda; Jun Matsushima; Yasutsugu Fukushima

Respiratory Medicine Case Reports (Jan 2024)

Case report of a patient with stage IV lung adenocarcinoma and uncommon/compound EGFR mutations who responded to afatinib

Hisanori Hirokawa,
Hirokuni Hirata,
Hayase Azuma,
Kei Sugitate,
Sayo Soda,
Jun Matsushima,
Yasutsugu Fukushima

Affiliations

Hisanori Hirokawa: Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University, Saitama Medical Center, 2-1-50 Minamikoshigaya, Koshigaya, Saitama, 343-0845, Japan
Hirokuni Hirata: Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University, Saitama Medical Center, 2-1-50 Minamikoshigaya, Koshigaya, Saitama, 343-0845, Japan; Corresponding author.
Hayase Azuma: Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University, Saitama Medical Center, 2-1-50 Minamikoshigaya, Koshigaya, Saitama, 343-0845, Japan
Kei Sugitate: Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University, Saitama Medical Center, 2-1-50 Minamikoshigaya, Koshigaya, Saitama, 343-0845, Japan
Sayo Soda: Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University, 880 Kitakobayashi, Shimotusga-gun, Tochigi, 321-0293, Japan
Jun Matsushima: Department of Pathology, Dokkyo Medical University, Saitama Medical Center, 2-1-50 Minamikoshigaya, Koshigaya, Saitama, 343-0845, Japan
Yasutsugu Fukushima: Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University, Saitama Medical Center, 2-1-50 Minamikoshigaya, Koshigaya, Saitama, 343-0845, Japan

Journal volume & issue: Vol. 51
p. 102094

Abstract

Read online

There is no established treatment for lung adenocarcinoma with uncommon/compound epidermal growth factor receptor (EGFR) mutations. We report a case of a 73-year-old man with stage IVB lung adenocarcinoma harboring E709G and L861Q EGFR mutations. After 2 months of afatinib treatment, significant tumor shrinkage was observed, and the patient's condition remained stable for 1 year. This case highlights the potential effectiveness of afatinib for treating rare stage IV lung adenocarcinoma with these specific EGFR mutations.

Published in Respiratory Medicine Case Reports

ISSN: 2213-0071 (Online)
Publisher: Elsevier
Country of publisher: Netherlands
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the respiratory system
Website: http://www.journals.elsevier.com/respiratory-medicine-case-reports/

About the journal

Abstract

Keywords